SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD. Financials Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
Equities
605016
CNE1000052N4
Food Processing
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.02 CNY | +1.26% |
|
+3.90% | +2.22% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,452 | 3,847 | 7,056 | 7,212 | - | - |
| Enterprise Value (EV) 1 | 4,452 | 3,847 | 7,056 | 7,212 | 7,212 | 7,212 |
| P/E ratio | 39 x | 25.5 x | 36.4 x | 26 x | 19.4 x | 15.4 x |
| Yield | - | 0.78% | - | 0.07% | 0.1% | 0.14% |
| Capitalization / Revenue | 6.81 x | 5.33 x | 8.13 x | 6.01 x | 4.46 x | 3.87 x |
| EV / Revenue | 6.81 x | 5.33 x | 8.13 x | 6.01 x | 4.46 x | 3.87 x |
| EV / EBITDA | 26.6 x | 17.1 x | 26.2 x | 20.9 x | 16.1 x | 12.7 x |
| EV / FCF | - | -158 x | -60.2 x | -42.7 x | 33.1 x | 24.9 x |
| FCF Yield | - | -0.63% | -1.66% | -2.34% | 3.02% | 4.02% |
| Price to Book | 3.7 x | 2.86 x | 4.68 x | 4.1 x | 3.44 x | 2.87 x |
| Nbr of stocks (in thousands) | 248,528 | 248,528 | 248,528 | 248,528 | - | - |
| Reference price 2 | 17.91 | 15.48 | 28.39 | 29.02 | 29.02 | 29.02 |
| Announcement Date | 3/1/22 | 3/12/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 653.4 | 721.9 | 868.3 | 1,200 | 1,617 | 1,864 |
| EBITDA 1 | - | 167.4 | 224.4 | 269.8 | 345 | 449 | 570 |
| EBIT 1 | - | 120.2 | 176.5 | 224.7 | 319.5 | 429.7 | 541 |
| Operating Margin | - | 18.4% | 24.45% | 25.88% | 26.62% | 26.57% | 29.03% |
| Earnings before Tax (EBT) 1 | - | 118.8 | 173.1 | 221.5 | 318.5 | 426.7 | 539 |
| Net income 1 | 95.55 | 104.5 | 150.8 | 193 | 277 | 371.7 | 469 |
| Net margin | - | 15.99% | 20.89% | 22.23% | 23.08% | 22.99% | 25.16% |
| EPS 2 | 0.5153 | 0.4592 | 0.6071 | 0.7800 | 1.115 | 1.493 | 1.890 |
| Free Cash Flow 1 | - | - | -24.42 | -117.3 | -169 | 218 | 290 |
| FCF margin | - | - | -3.38% | -13.51% | -14.08% | 13.48% | 15.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 48.55% | 50.88% |
| FCF Conversion (Net income) | - | - | - | - | - | 58.65% | 61.83% |
| Dividend per Share 2 | - | - | 0.1214 | - | 0.0200 | 0.0300 | 0.0400 |
| Announcement Date | 3/29/21 | 3/1/22 | 3/12/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -24.4 | -117 | -169 | 218 | 290 |
| ROE (net income / shareholders' equity) | - | 10.3% | 11.8% | 13.4% | 16% | 17.8% | 18.8% |
| ROA (Net income/ Total Assets) | - | - | 10.9% | 12% | 13.7% | 15.4% | 17.3% |
| Assets 1 | - | - | 1,377 | 1,613 | 2,022 | 2,413 | 2,711 |
| Book Value Per Share 2 | - | 4.840 | 5.410 | 6.070 | 7.080 | 8.430 | 10.10 |
| Cash Flow per Share 2 | - | 0.3900 | - | 0.7800 | 0.5300 | 1.060 | - |
| Capex 1 | - | - | 174 | 312 | 161 | 163 | 188 |
| Capex / Sales | - | - | 24.14% | 35.92% | 13.37% | 10.08% | 10.09% |
| Announcement Date | 3/29/21 | 3/1/22 | 3/12/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.02
CNY
Average target price
33
CNY
Spread / Average Target
+13.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.22% | 998M | |
| -4.86% | 2.97B | |
| -3.48% | 1.9B | |
| +0.51% | 1.84B | |
| -0.18% | 1.17B | |
| -11.03% | 1.07B | |
| +12.53% | 910M | |
| -8.80% | 904M | |
| -0.09% | 902M | |
| +3.50% | 826M |
- Stock Market
- Equities
- 605016 Stock
- Financials Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.